BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome

George Z. Rassidakis, L. Jeffrey Medeiros, Timothy J. McDonnell, Simonetta Viviani, Valeria Bonfante, Gianpaolo Nadali, Theodoros P. Vassilakopoulos, Roberto Giardini, Marco Chilosi, Christos Kittas, Alessandro M. Gianni, Gianni Bonadonna, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: BAX, a proapoptotic member of the BCL-2 family of proteins, has been detected in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's disease (HD), but its clinical significance is unknown. Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD. Design: Patients with biopsy-proven HD were eligible if they were untreated previously and if pretreatment paraffin-embedded tumor tissue was available. BAX was detected by immunohistochemistry without knowledge of clinical features or outcome. A tumor was considered as positive if any number of HRS cells expressed BAX, but other cutoffs of BAX expression were examined for analysis of clinical outcome. Results: We identified 260 patients with HD. The median age was 31 years, and 55% were male. HRS cells expressed BAX in 181 of 195 (93%) nodular sclerosis, 47 of 48 (98%) mixed cellularity, 1 case of lymphocyte depletion, all 6 unclassified classical HD, and all 10 lymphocyte predominance tumors. Using a cutoff of 50% positive HRS cells for BAX expression, the 5-year failure-free survival (FFS) for patients with high versus low BAX expression was 83 versus 93%, respectively (P = 0.19 by Log-rank) for 116 patients treated with doxorubicin, Neomycin, vinblastine, and dacarbazine or equivalent regimens; it was 78 versus 79%, respectively, for 79 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = 0.45 by Log-rank); it was 71 versus 81%, respectively, for 26 patients treated with nitrogen mustard, vincristine, prednisone, and procarbazine (P = 0.6 by Log-rank); and it was 72 versus 82% for 29 patients treated only with radiotherapy (P = 0.57 by Log-rank). The 5-year FFS was not statistically different when we used cutoffs of 20, 30, and 75% for BAX expression. Conclusion: BAX is often expressed by HRS cells in HD and does not correlate with FFS.

Original languageEnglish
Pages (from-to)488-493
Number of pages6
JournalClinical Cancer Research
Volume8
Issue number2
Publication statusPublished - 2002

Fingerprint

Reed-Sternberg Cells
Hodgkin Disease
Vinblastine
Vincristine
Prednisone
Survival
Radiotherapy
Lymphocyte Depletion
Procarbazine
Mechlorethamine
Neoplasms
Mitoxantrone
Dacarbazine
Neomycin
Sclerosis
Paraffin
Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rassidakis, G. Z., Medeiros, L. J., McDonnell, T. J., Viviani, S., Bonfante, V., Nadali, G., ... Sarris, A. H. (2002). BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome. Clinical Cancer Research, 8(2), 488-493.

BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease : Correlation with clinical outcome. / Rassidakis, George Z.; Medeiros, L. Jeffrey; McDonnell, Timothy J.; Viviani, Simonetta; Bonfante, Valeria; Nadali, Gianpaolo; Vassilakopoulos, Theodoros P.; Giardini, Roberto; Chilosi, Marco; Kittas, Christos; Gianni, Alessandro M.; Bonadonna, Gianni; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.

In: Clinical Cancer Research, Vol. 8, No. 2, 2002, p. 488-493.

Research output: Contribution to journalArticle

Rassidakis, GZ, Medeiros, LJ, McDonnell, TJ, Viviani, S, Bonfante, V, Nadali, G, Vassilakopoulos, TP, Giardini, R, Chilosi, M, Kittas, C, Gianni, AM, Bonadonna, G, Pizzolo, G, Pangalis, GA, Cabanillas, F & Sarris, AH 2002, 'BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome', Clinical Cancer Research, vol. 8, no. 2, pp. 488-493.
Rassidakis, George Z. ; Medeiros, L. Jeffrey ; McDonnell, Timothy J. ; Viviani, Simonetta ; Bonfante, Valeria ; Nadali, Gianpaolo ; Vassilakopoulos, Theodoros P. ; Giardini, Roberto ; Chilosi, Marco ; Kittas, Christos ; Gianni, Alessandro M. ; Bonadonna, Gianni ; Pizzolo, Giovanni ; Pangalis, Gerassimos A. ; Cabanillas, Fernando ; Sarris, Andreas H. / BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease : Correlation with clinical outcome. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 2. pp. 488-493.
@article{32a14516d682438e95b05424dcd0e182,
title = "BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome",
abstract = "Purpose: BAX, a proapoptotic member of the BCL-2 family of proteins, has been detected in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's disease (HD), but its clinical significance is unknown. Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD. Design: Patients with biopsy-proven HD were eligible if they were untreated previously and if pretreatment paraffin-embedded tumor tissue was available. BAX was detected by immunohistochemistry without knowledge of clinical features or outcome. A tumor was considered as positive if any number of HRS cells expressed BAX, but other cutoffs of BAX expression were examined for analysis of clinical outcome. Results: We identified 260 patients with HD. The median age was 31 years, and 55{\%} were male. HRS cells expressed BAX in 181 of 195 (93{\%}) nodular sclerosis, 47 of 48 (98{\%}) mixed cellularity, 1 case of lymphocyte depletion, all 6 unclassified classical HD, and all 10 lymphocyte predominance tumors. Using a cutoff of 50{\%} positive HRS cells for BAX expression, the 5-year failure-free survival (FFS) for patients with high versus low BAX expression was 83 versus 93{\%}, respectively (P = 0.19 by Log-rank) for 116 patients treated with doxorubicin, Neomycin, vinblastine, and dacarbazine or equivalent regimens; it was 78 versus 79{\%}, respectively, for 79 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = 0.45 by Log-rank); it was 71 versus 81{\%}, respectively, for 26 patients treated with nitrogen mustard, vincristine, prednisone, and procarbazine (P = 0.6 by Log-rank); and it was 72 versus 82{\%} for 29 patients treated only with radiotherapy (P = 0.57 by Log-rank). The 5-year FFS was not statistically different when we used cutoffs of 20, 30, and 75{\%} for BAX expression. Conclusion: BAX is often expressed by HRS cells in HD and does not correlate with FFS.",
author = "Rassidakis, {George Z.} and Medeiros, {L. Jeffrey} and McDonnell, {Timothy J.} and Simonetta Viviani and Valeria Bonfante and Gianpaolo Nadali and Vassilakopoulos, {Theodoros P.} and Roberto Giardini and Marco Chilosi and Christos Kittas and Gianni, {Alessandro M.} and Gianni Bonadonna and Giovanni Pizzolo and Pangalis, {Gerassimos A.} and Fernando Cabanillas and Sarris, {Andreas H.}",
year = "2002",
language = "English",
volume = "8",
pages = "488--493",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease

T2 - Correlation with clinical outcome

AU - Rassidakis, George Z.

AU - Medeiros, L. Jeffrey

AU - McDonnell, Timothy J.

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Nadali, Gianpaolo

AU - Vassilakopoulos, Theodoros P.

AU - Giardini, Roberto

AU - Chilosi, Marco

AU - Kittas, Christos

AU - Gianni, Alessandro M.

AU - Bonadonna, Gianni

AU - Pizzolo, Giovanni

AU - Pangalis, Gerassimos A.

AU - Cabanillas, Fernando

AU - Sarris, Andreas H.

PY - 2002

Y1 - 2002

N2 - Purpose: BAX, a proapoptotic member of the BCL-2 family of proteins, has been detected in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's disease (HD), but its clinical significance is unknown. Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD. Design: Patients with biopsy-proven HD were eligible if they were untreated previously and if pretreatment paraffin-embedded tumor tissue was available. BAX was detected by immunohistochemistry without knowledge of clinical features or outcome. A tumor was considered as positive if any number of HRS cells expressed BAX, but other cutoffs of BAX expression were examined for analysis of clinical outcome. Results: We identified 260 patients with HD. The median age was 31 years, and 55% were male. HRS cells expressed BAX in 181 of 195 (93%) nodular sclerosis, 47 of 48 (98%) mixed cellularity, 1 case of lymphocyte depletion, all 6 unclassified classical HD, and all 10 lymphocyte predominance tumors. Using a cutoff of 50% positive HRS cells for BAX expression, the 5-year failure-free survival (FFS) for patients with high versus low BAX expression was 83 versus 93%, respectively (P = 0.19 by Log-rank) for 116 patients treated with doxorubicin, Neomycin, vinblastine, and dacarbazine or equivalent regimens; it was 78 versus 79%, respectively, for 79 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = 0.45 by Log-rank); it was 71 versus 81%, respectively, for 26 patients treated with nitrogen mustard, vincristine, prednisone, and procarbazine (P = 0.6 by Log-rank); and it was 72 versus 82% for 29 patients treated only with radiotherapy (P = 0.57 by Log-rank). The 5-year FFS was not statistically different when we used cutoffs of 20, 30, and 75% for BAX expression. Conclusion: BAX is often expressed by HRS cells in HD and does not correlate with FFS.

AB - Purpose: BAX, a proapoptotic member of the BCL-2 family of proteins, has been detected in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's disease (HD), but its clinical significance is unknown. Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD. Design: Patients with biopsy-proven HD were eligible if they were untreated previously and if pretreatment paraffin-embedded tumor tissue was available. BAX was detected by immunohistochemistry without knowledge of clinical features or outcome. A tumor was considered as positive if any number of HRS cells expressed BAX, but other cutoffs of BAX expression were examined for analysis of clinical outcome. Results: We identified 260 patients with HD. The median age was 31 years, and 55% were male. HRS cells expressed BAX in 181 of 195 (93%) nodular sclerosis, 47 of 48 (98%) mixed cellularity, 1 case of lymphocyte depletion, all 6 unclassified classical HD, and all 10 lymphocyte predominance tumors. Using a cutoff of 50% positive HRS cells for BAX expression, the 5-year failure-free survival (FFS) for patients with high versus low BAX expression was 83 versus 93%, respectively (P = 0.19 by Log-rank) for 116 patients treated with doxorubicin, Neomycin, vinblastine, and dacarbazine or equivalent regimens; it was 78 versus 79%, respectively, for 79 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = 0.45 by Log-rank); it was 71 versus 81%, respectively, for 26 patients treated with nitrogen mustard, vincristine, prednisone, and procarbazine (P = 0.6 by Log-rank); and it was 72 versus 82% for 29 patients treated only with radiotherapy (P = 0.57 by Log-rank). The 5-year FFS was not statistically different when we used cutoffs of 20, 30, and 75% for BAX expression. Conclusion: BAX is often expressed by HRS cells in HD and does not correlate with FFS.

UR - http://www.scopus.com/inward/record.url?scp=0036189683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189683&partnerID=8YFLogxK

M3 - Article

C2 - 11839668

AN - SCOPUS:0036189683

VL - 8

SP - 488

EP - 493

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -